Why Medivation Inc. Stock Sank 14% in December
Medivation shares plunge in December on fears of a price war breaking out between cancer drug developers. Find out if this dip is worth buying.
These 3 Biotechs Are Looking at a Happy New Year
Which drugs are poised to carry their makers into a healthy 2015? Industry Focus has three top picks.